- Molecular NameTranylcypromine
- SynonymNA
- Weight133.194
- Drugbank_IDDB00752
- ACS_NO155-09-9
- Show 3D model
- LogP (experiment)1.6
- LogP (predicted, AB/LogP v2.0)1.29
- pka8.2
- LogD (pH=7, predicted)0.07
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-0.2
- LogSw (predicted, AB/LogsW2.0)0.47
- Sw (mg/ml) (predicted, ACD/Labs)4.62
- No.of HBond Donors2
- No.of HBond Acceptors1
- No.of Rotatable Bonds1
- TPSA26.02
- StatusFDA approved
- AdministrationN/A
- PharmacologyA psychoactive drug of the phenethylamine and amphetamine chemical classes which acts as a monoamine oxidase inhibitor (MAOI)—it is a nonselective and irreversible inhibitor of the enzyme monoamine oxidase (MAO).[1] It is used as an antidepressant and anxiolytic agent in the clinical treatment of mood and anxiety disorders, respectively.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability50.0
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmLiver (by enzymes CYP2A6, CYP2C19, CYP2D6, MAOA, and MAOB)
- Half life2 h
- ExcretionUrine, feces
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityIn overdosage, some patients exhibit insomnia, restlessness and anxiety, progressing in severe cases to agitation, mental confusion and incoherence. Hypotension, dizziness, weakness and drowsiness may occur, progressing in severe cases to extreme dizziness and shock. A few patients have displayed hypertension with severe headache and other symptoms. Rare instances have been reported in which hypertension was accompanied by twitching or myoclonic fibrillation of skeletal muscles with hyperpyrexia, sometimes progressing to generalized rigidity and coma.
- LD50 (rat)N/A
- LD50 (mouse)N/A